专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160186261A1 PREVOTELLA COPRI AND ENHANCED SUSCEPTIBILITY TO ARTHRITIS 审中-公开
标题翻译： PREVOTELLA COPRI和增强对ARTHRITIS的抵制能力
公开(公告)号：US20160186261A1
公开(公告)日：2016-06-30
申请号：US14532586
申请日：2014-11-04
申请人： Jose U. Scher , Andrew Sczesnak , Randy S. Longman , Nicola Segata , Carles Ubeda , Eric G. Pamer , Steven B. Abramson , Curtis Huttenhower , Dan R. Littman , Hannah Fehlner-Peach
发明人： Jose U. Scher , Andrew Sczesnak , Randy S. Longman , Nicola Segata , Carles Ubeda , Eric G. Pamer , Steven B. Abramson , Curtis Huttenhower , Dan R. Littman , Hannah Fehlner-Peach
IPC分类号： C12Q1/68 , G01N33/569
CPC分类号： C12Q1/6883 , C12Q1/689 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/564 , G01N33/56911
摘要： Methods, reagents and compositions thereof for predicting risk for NORA onset in susceptible individuals, diagnosing NORA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of at least one of SEQ ID NOs: 1-19 and/or at least one of a KO presented in either of Tables S4 or S5 serves as a biomarker for the above indications.
摘要翻译：本文描述了用于预测敏感个体中NORA起始的风险的方法，试剂及其组合物，诊断NORA起始和/或评估用于治疗RA的治疗方案的功效。确定SEQ ID NO：1-19和/或表S4或S5中任一个中呈现的KO中的至少一个的量用作上述适应症的生物标志物。

2. 发明申请

US20160136122A1 METHODS FOR TREATING PSORIATIC ARTHRITIS 审中-公开
标题翻译：治疗精神障碍的方法
公开(公告)号：US20160136122A1
公开(公告)日：2016-05-19
申请号：US14885084
申请日：2015-10-16
申请人： Jose U. Scher , Carles Ubeda , Dan R. Littman , Eric G. Pamer , Steven B. Abramson , Sergei B. Koralov
发明人： Jose U. Scher , Carles Ubeda , Dan R. Littman , Eric G. Pamer , Steven B. Abramson , Sergei B. Koralov
IPC分类号： A61K31/20 , A61K35/74 , A61K31/19
CPC分类号： A61K31/20 , A61K31/19 , A61K35/74 , A61K45/06
摘要： Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.
摘要翻译：用于治疗牛皮癣关节炎（PsA）的方法，试剂及其组合物包括在本文中。

3. 发明申请

US20120065094A1 METHODS AND KITS FOR DIAGNOSING OSTEOARTHRITIS AND PREDICTING PROGRESSION 有权
标题翻译：用于诊断OSTEOARTHRITIS和预测进展的方法和工具
公开(公告)号：US20120065094A1
公开(公告)日：2012-03-15
申请号：US13232715
申请日：2011-09-14
申请人： Mukundan Attur , Steven B. Abramson
发明人： Mukundan Attur , Steven B. Abramson
IPC分类号： C40B30/04 , C07K16/40 , C07K16/24 , C12Q1/68 , C07K16/22
CPC分类号： G01N33/74 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , G01N2333/475 , G01N2333/52 , G01N2333/545 , G01N2333/964 , G01N2333/96494 , G01N2800/105 , G01N2800/56
摘要： This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.
摘要翻译：本公开涉及用于诊断骨关节炎和用于确定受试者中骨关节炎进展的方法和试剂盒。

4. 发明申请

US20100129798A1 DETECTING GENETIC PREDISPOSITION TO OSTEOARTHRITIS ASSOCIATED CONDITIONS 审中-公开
公开(公告)号：US20100129798A1
公开(公告)日：2010-05-27
申请号：US12435257
申请日：2009-05-04
申请人： Steven B. Abramson , Nazneen Aziz , Hwa-Ying Wang , Kenneth Huttner , Jack F. Bukowski , Mukundian Attur
发明人： Steven B. Abramson , Nazneen Aziz , Hwa-Ying Wang , Kenneth Huttner , Jack F. Bukowski , Mukundian Attur
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/172
摘要： This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions.

5. 发明申请

US20100015129A1 Methods of using F-spondin as a biomarker for cartilage degenerative conditions and bone diseases 审中-公开
标题翻译：使用F-spondin作为软骨退行性疾病和骨病的生物标志物的方法
公开(公告)号：US20100015129A1
公开(公告)日：2010-01-21
申请号：US12455296
申请日：2009-05-29
申请人： Steven B. Abramson , Mukundan Attur , Ashok Amin , Glyn Palmer
发明人： Steven B. Abramson , Mukundan Attur , Ashok Amin , Glyn Palmer
IPC分类号： A61K39/395 , C12Q1/68 , G01N33/00 , G01N33/53 , A61K31/7088
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/5041 , G01N33/6887 , G01N33/6893
摘要： Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions. The use of F-spondin, an active fragment thereof, or a modulator thereof for enhancing cartilage repair or preventing or treating cartilage degeneration, degenerative diseases or arthritic conditions is also provided.
摘要翻译：提供了通过测量F-spondin的表达水平来鉴定具有或具有发展为骨关节炎或其它软骨退行性疾病风险的受试者的方法。公开了用于确定和测定个体患者中F-spondin的存在的测定，试剂盒和方法。描述了用于测定，试剂盒和方法的寡核苷酸探针和引物。公开了用于鉴定调节F-spondin水平的表达和/或功能或用于确定和评估个体对药物和治疗剂的反应的候选化合物的测定和方法。本发明还涉及F-spondin的调节，特别是F-spondin的抑制，用于增加或刺激骨形成和/或生长并介导骨疾病，病症或病症的缓解。还提供了用于增强软骨修复或预防或治疗软骨变性，退行性疾病或关节炎病症的F-斯朋素，其活性片段或其调节剂的用途。

6. 发明申请

US20150374760A1 METHODS FOR TREATING PSORIASIS AND PSORIATIC ARTHRITIS 审中-公开
标题翻译：治疗PSORIASIS和PSORIATIC ARTHRITIS的方法
公开(公告)号：US20150374760A1
公开(公告)日：2015-12-31
申请号：US14682344
申请日：2015-04-09
申请人： Jose U. Scher , Carles Ubeda , Dan R. Littman , Eric G. Pamer , Steven B. Abramson
发明人： Jose U. Scher , Carles Ubeda , Dan R. Littman , Eric G. Pamer , Steven B. Abramson
IPC分类号： A61K35/74
CPC分类号： A61K35/74
摘要： Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) and psoriasis (Ps) are encompassed herein, as are methods for identifying pathogenic dysbiosis in a subject, the presence of which is a positive indicator of risk for developing PsA or of the presence of PsA in a subject with arthritic symptoms.
摘要翻译：本文包括用于治疗银屑病关节炎（PsA）和牛皮癣（Ps）的方法，试剂及其组合物，以及用于鉴定受试者中致病性失语症的方法，其存在是发展PsA或存在的风险的积极指标的PsA在关节炎症状的主题。

7. 发明申请

US20140274766A1 METHODS OF USING F-SPONDIN AS A BIOMARKER FOR CARTILAGE DEGENERATIVE CONDITIONS AND BONE DISEASES 审中-公开
标题翻译：使用F-SPONDIN作为生物标记物用于治疗退行性疾病和骨髓疾病的方法
公开(公告)号：US20140274766A1
公开(公告)日：2014-09-18
申请号：US14155491
申请日：2014-01-15
申请人： Steven B. Abramson , Mukundan Attur , Glyn Palmer , Ashok Amin
发明人： Steven B. Abramson , Mukundan Attur , Glyn Palmer , Ashok Amin
IPC分类号： C12Q1/68 , G01N33/50 , G01N33/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/5041 , G01N33/6887 , G01N33/6893
摘要： Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions. The use of F-spondin, an active fragment thereof, or a modulator thereof for enhancing cartilage repair or preventing or treating cartilage degeneration, degenerative diseases or arthritic conditions is also provided.
摘要翻译：提供了通过测量F-spondin的表达水平来鉴定具有或具有发展为骨关节炎或其它软骨退行性疾病风险的受试者的方法。公开了用于确定和测定个体患者中F-spondin的存在的测定，试剂盒和方法。描述了用于测定，试剂盒和方法的寡核苷酸探针和引物。公开了用于鉴定调节F-spondin水平的表达和/或功能或用于确定和评估个体对药物和治疗剂的反应的候选化合物的测定和方法。本发明还涉及F-spondin的调节，特别是F-spondin的抑制，用于增加或刺激骨形成和/或生长并介导骨疾病，病症或病症的缓解。还提供了用于增强软骨修复或预防或治疗软骨变性，退行性疾病或关节炎病症的F-斯朋素，其活性片段或其调节剂的用途。

8. 发明授权

US5919775A Method for inhibiting expression of inducible nitric oxide synthase with tetracycline 失效
标题翻译：用四环素抑制诱导型一氧化氮合酶表达的方法
公开(公告)号：US5919775A
公开(公告)日：1999-07-06
申请号：US61286
申请日：1998-04-16
申请人： Ashok R. Amin , Steven B. Abramson , Lorne M. Golub , Nungavaram S. Ramamurthy , Thomas F. McNamara , Robert A. Greenwald , Howard Trachtman
发明人： Ashok R. Amin , Steven B. Abramson , Lorne M. Golub , Nungavaram S. Ramamurthy , Thomas F. McNamara , Robert A. Greenwald , Howard Trachtman
IPC分类号： A61K31/65 , A61P13/12 , A61P19/02 , A61P29/00 , A61P43/00
CPC分类号： A61K31/65
摘要： The invention is a method of inhibiting the production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo biological system. The method employs a tetracycline compound to inhibit the production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the biological system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
摘要翻译：本发明是一种在体内，体外或离体生物体系中抑制一氧化氮（NO）的产生的方法。该方法采用四环素化合物抑制NO的产生和/或抑制一氧化氮合酶（iNOS）的诱导型异构体的表达或活性。优选地，四环素化合物对金属蛋白酶具有抑制活性。此外，优选的是，四环素化合物以系统中几乎没有或没有抗菌活性的量提供给生物系统。因此，优选的四环素化合物是四环素化合物，其被修饰以降低或消除其抗微生物活性。该方法可用于治疗以iNOS介导的NO产生为特征的哺乳动物的医疗状况，包括例如炎性病症。

9. 发明授权

US5789395A Method of using tetracycline compounds for inhibition of endogenous nitric oxide production 失效
标题翻译：使用四环素化合物抑制内源性一氧化氮产生的方法
公开(公告)号：US5789395A
公开(公告)日：1998-08-04
申请号：US697815
申请日：1996-08-30
申请人： Ashok R. Amin , Steven B. Abramson , Lorne M. Golub , Nungavaram S. Ramamurthy , Thomas F. McNamara , Robert A. Greenwald , Howard Trachtman
发明人： Ashok R. Amin , Steven B. Abramson , Lorne M. Golub , Nungavaram S. Ramamurthy , Thomas F. McNamara , Robert A. Greenwald , Howard Trachtman
IPC分类号： A61K31/65 , A61P13/12 , A61P19/02 , A61P29/00 , A61P43/00 , C12N9/99 , C12N9/04 , C12N9/06
CPC分类号： A61K31/65
摘要： A method is disclosed for inhibiting endogenous production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo mammalian system. The method employs a tetracycline compound to inhibit production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the mammalian system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
摘要翻译：公开了用于抑制体内，体外或离体哺乳动物系统中一氧化氮（NO）的内源性产生的方法。该方法采用四环素化合物抑制NO的产生和/或抑制一氧化氮合酶（iNOS）的诱导型亚型的表达或活性。优选地，四环素化合物对金属蛋白酶具有抑制活性。此外，优选的是，四系环化合物以系统中几乎没有或没有抗菌活性的量提供给哺乳动物系统。因此，优选的四环素化合物是四环素化合物，其被修饰以降低或消除其抗微生物活性。该方法可用于治疗以iNOS介导的NO产生为特征的哺乳动物的医疗状况，包括例如炎性病症。

10. 发明申请

US20160222436A1 CAUSATIVE AGENTS AND DIAGNOSTIC METHODS RELATING TO RHEUMATOID ARTHRITIS 有权
标题翻译：与炎热性脑病相关的原因和诊断方法
公开(公告)号：US20160222436A1
公开(公告)日：2016-08-04
申请号：US14351622
申请日：2012-10-15
申请人： Steven B. ABRAMSON , Jose U. SCHER , Dan R. LITTMAN , Eric G. PAMER
发明人： Steven B. Abramson , Jose U. Scher , Dan R. Littman , Eric G. Pamer , Carles Ubeda , Randy S. Longman , Andrew Sczesnak
IPC分类号： C12Q1/68
CPC分类号： C12Q1/689 , C12Q1/18 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/56911 , G01N2800/102 , G01N2800/50 , G01N2800/52
摘要： Methods, reagents and compositions thereof for predicting RA onset in susceptible individuals, diagnosing RA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of a particular bacterial species comprising SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 (SEQ ID NO: 1+bacteria) serves as a biomarker for the above indications.
摘要翻译：本文描述了用于预测敏感个体的RA发作的方法，试剂及其组合物，诊断RA起始和/或评价用于治疗RA的治疗方案的功效。确定包含SEQ ID NO：1，SEQ ID NO：2或SEQ ID NO：3（SEQ ID NO：1 +细菌）的特定细菌种类的量用作上述适应症的生物标志物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式